U2AF1 and acute myeloid leukemia: As is well known, RNA splicing factor gene U2AF1 and isocitrate dehydrogenase gene IDH1/2 mutations are recurrent in de novo AML especially in CN-AML, and have a prognostic impact on assessing treatment outcome [14, 15].